Performance Food Group (PFGC) Appoints Laura Flanagan to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Performance Food Group (PFGC) Completes the Acquisition of Core-Mark
September 1, 2021 4:34 PM EDTPerformance Food Group Company (NYSE: PFGC) announced today that it has completed the acquisition of Core-Mark Holding Company, Inc. (Core-Mark). The transaction creates a best-in-class convenience business within PFGs Vistar segment that includes the Core-Mark and Eby-Brown businesses. The expanded convenience business will continue to operate under Core-Mark and will be headquartered in Westlake, Texas with Eby maintaining ongoing operations in Naperville, Illinois. Scott McPherson will continue in his role as President and Chief Executive Officer of Core-Mark, and Tom Wake will continue as President and Chief Executive Officer of Eby-Brown, reporting to... More
Pre-Open Stock Movers 08/31: (ACIU) (SONN) (APPS) Higher; (ZM) (AMWD) (CHS) Lower (more...)
August 31, 2021 9:19 AM EDTPre-Open Stock Movers:
AC Immune SA (NASDAQ: ACIU) 74.5% HIGHER; announced that Genentech, a member of the Roche Group, has informed the Company that Lauriet, a placebo-controlled Phase 2 study evaluating the safety and efficacy of the investigational anti-tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimers disease (AD), met one of its co-primary endpoints, ADAS-Cog11. The second co-primary endpoint, ADCS-ADL, was not met. Safety data showed that semorinemab is well tolerated with an acceptable safety profile and no unanticipated safety signals.
Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:... More
After-Hours Stock Movers 08/30: (SONN) (APPS) (PFGC) Higher; (ZM) (STNE) (SOL) Lower (more...)
August 30, 2021 6:25 PM EDTAfter-Hours Movers:
Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) 27% HIGHER; announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the company's Fully Human Albumin Binding (FHAB) platform. The target indications for SON-1410 will be melanoma and renal cancers.
Zoom (NASDAQ: ZM) 11.5% LOWER; reported Q2 EPS of $1.36, $0.34 better... More
Performance Food Group (PFGC) gains 4% on S&P MidCap 400 addition
August 30, 2021 5:20 PM EDTPerformance Food Group (NYSE: PFGC) gains 4% on S&P MidCap 400 addition.
... MorePerformance Food Group (PFGC), Digital Turbine (APPS) Added to S&P MidCap 400
August 30, 2021 5:17 PM EDTPerformance Food Group Co. (NYSE: PFGC) will replace TreeHouse Foods Inc. (NYSE: THS) in the S&P MidCap 400, and TreeHouse Foods will replace Core-Mark Holding Company Inc. (NASDAQ: CORE) in the S&P SmallCap... More

